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Resveratrol (trans-3,5,40-trihydroxystilbene) is a naturally occurring polyphenol with cancer chemopreventive properties in preclinical
models of carcinogenesis, including those of colorectal cancer. Recently, a variety of analogues of resveratrol have been synthesised
and investigated in in vitro assays. One analogue, 3,4,5,40-tetramethoxystilbene (DMU 212), showed preferential growth-inhibitory
and proapoptotic properties in transformed cells, when compared with their untransformed counterparts. As part of a
chemoprevention drug development programme, the pharmacokinetic properties of DMU 212 were compared with those of
resveratrol in the plasma, liver, kidney, lung, heart, brain and small intestinal and colonic mucosa of mice. DMU 212 or resveratrol
(240mgkg
 1) were administered intragastrically, and drug concentrations were measured by HPLC. Metabolites were characterised
by cochromatography with authentic reference compounds and were identified by mass spectrometry. The ratios of area of plasma
or tissue concentration vs time curves of resveratrol over DMU 212 (AUCres/AUCDMU212) for the plasma, liver, small intestinal and
colonic mucosa were 3.5, 5, 0.1 and 0.15, respectively. Thus, resveratrol afforded significantly higher levels than DMU 212 in the
plasma and liver, while DMU 212 exhibited superior availability compared to resveratrol in the small intestine and colon. Resveratrol
was metabolised to its sulphate or glucuronate conjugates, while DMU 212 underwent metabolic hydroxylation or single and double
O-demethylation. DMU 212 and resveratrol inhibited the growth of human-derived colon cancer cells HCA-7 and HT-29 in vitro with
IC50 values of between 6 and 26mM. In the light of the superior levels achieved in the gastrointestinal tract after the administration of
DMU 212, when compared to resveratrol, the results provide a good rationale to evaluate DMU 212 as a colorectal cancer
chemopreventive agent.
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Resveratrol (trans 3,5,40-trihydroxystilbene, for structure see
Figure 1) is a phytoalexin generated in response to environmental
stress or pathogenic attack in grapes, mulberries, cranberries,
peanuts and plants of the Cassia quinquangulata family.
Resveratrol inhibits diverse cellular events associated with the
three major stages of carcinogenesis: initiation, promotion and
progression (Jang et al, 1997). Since this discovery, resveratrol has
been the subject of a large number of preclinical and mechanistic
studies. The cancer chemopreventive potential of resveratrol has
been demonstrated in the models of carcinogenesis in vivo and in
cells in vitro. It inhibits the proliferation of a variety of cancer cell
lines (for a review, see Gusman et al, 2001), formation of
preneoplastic lesions in the 7,12-dimethylbenz(a)anthracene-
(DMBA) induced mouse mammary organ culture model (Bhat
et al, 2001) and benzo(a)pyrene-induced transformation of rat
tracheal epithelial cells (Jang et al, 1997). In animal studies,
resveratrol interfered with the formation of azoxymethane-(AOM)
induced aberrant crypt foci in rat colon (Tessitore et al, 2000),
attenuated oesophageal carcinoma formation in rats that received
N-nitrosomethylbenzylamine (NMBA) (Li et al, 2002), decreased
the number of adenomas in the small intestine and suppressed
tumour formation in the colon of Apc
Minþ mice (Schneider et al,
2001) and reduced mammary tumour formation in N-methyl-N-
nitrosourea-(NMU) treated rats (Bhat et al, 2001). Resveratrol has
been reported to possess a variety of anti-inflammatory, antiplate-
let and both pro- and antioestrogenic effects (Bertelli et al, 1996;
Gehm et al, 1997; Jang et al, 1997; Uenobe et al, 1997). It exerts a
wide variety of biological effects germane to cancer chemopreven-
tion, including the inhibition of cytochrome P450 enzyme
expression activity (Chun et al, 1999; Guengerich et al, 2003),
induction of apoptosis (Mahyar-Roemer et al, 2001, 2002),
modulation of components of the cell cycle machinery (Schneider
et al, 2000; Wolter et al, 2001), decrease in cyclooxygenase 1
(COX-1) activity and COX-2 expression (Subbaramaiah et al, 1998;
Mutoh et al, 2000; Li et al, 2002), antioxidation (Sgambato et al,
2001), inhibition of activities of protein kinase C and D (Haworth Revised 17 October 2003; accepted 17 November 2003
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sand Avkiran, 2001; Slater et al, 2003) and decrease in the activity of
transcription factors NFkB and AP-1 (Surh et al, 2001; Banerjee
et al, 2002). As is the case with many polyphenols with putative
cancer chemopreventive properties, the systemic bioavailability of
resveratrol is probably poor. This notion is borne out by studies in
mice, rats and dogs, which suggest consistently that resveratrol is
well absorbed but avidly glucuronidated and sulphated both in the
liver and in intestinal epithelial cells (Asensi et al, 2002;Juan et al,
2002; Marier et al, 2002). One study in humans also hints at a poor
bioavailability of resveratrol (Goldberg et al, 2003). In the wake of
the discovery of the interesting pharmacological properties of
resveratrol, the trihydroxystilbene scaffold has become the subject
of imaginative synthetic manipulations by medicinal chemists with
the aim of generating novel congeners of pharmacological interest
and to characterise structural features, which impart activity to the
molecule. These structural alterations have been aimed at the
optimisation of the cytochrome P450 enzyme-inhibitory and
antimutagenic potencies of the molecule (Chun et al, 2001; Kim
et al, 2002), its antioxidant activity (Lu et al, 2001), its apoptosis-
inducing and growth-inhibitory activity (Lu et al, 2001; Nam et al,
2001; Kim et al, 2002) and its ability to inhibit cell transformation
(She et al, 2003). These chemical synthetic attempts have
predominantly been concerned with the introduction of additional
hydroxy moieties into the trihydroxystilbene framework and with
various degrees of methylation of the phenol groups. An especially
auspicious finding concerning these analogues is the fact that
3,4,5,40-tetrahydroxystilbene, resveratrol with an additional hydro-
xy moiety, and its O-methylated congener, 3,4,5,40-tetramethox-
ystilbene (DMU 212, for structure see Figure 1), were capable of
preferentially interfering with the proliferation and survival of
transformed human lung-derived cells, with much lower growth-
inhibitory and apoptotic properties in their untransformed
counterparts (Lu et al, 2001). In contrast, resveratrol did not
possess this discriminatory potential. Furthermore, DMU 212 is
currently under preclinical evaluation as a potential antitumour
prodrug that undergoes metabolic activation by certain cyto-
chrome P450 enzymes (Potter et al, 2002a). In the light of the
availability of pharmacologically interesting stilbene analogues, it
seems appropriate to compare the cancer chemopreventive
potential of resveratrol in preclinical models with those of its
congeners, which have been shown to possess increased potency in
relevant in vitro assays. Before embarking on such efficacy studies,
it is desirable to find out if resveratrol congeners, to be evaluated
as potential chemopreventive agents, possess adequate bioavail-
ability in the tissues in which malignancies are to be prevented.
Such pharmacokinetic exploration should be an essential part of
the chemopreventive drug discovery process. Mindful of these
considerations, we chose DMU 212, one of the most interesting
resveratrol analogues described thus far (Lu et al, 2001; Potter et al,
2002a), and compared its levels in murine tissues after oral
administration with those of resveratrol. Thus, the hypothesis was
tested that a replacement of the phenol functionalities in
resveratrol by methoxy moieties and an addition of a further
methoxy group impinge on the pharmacokinetic properties of the
parent molecule. Additionally, DMU 212 was compared with
resveratrol in terms of their metabolism in the mouse in vivo and
in liver homogenate preparations in vitro. The mouse is the animal
species frequently used in cancer chemoprevention efficacy
studies. Finally, we compared the ability of DMU 212 and
resveratrol to interfere with the growth of human-derived colon
cancer cells. Overall, the study was designed to help rationalise the
choice of resveratrol analogues for further testing for potential
usefulness as cancer chemopreventive agents.
MATERIALS AND METHODS
Reagents, animals and cells
Resveratrol, DMU 212 and its congeners referred to in this work
are exclusively the trans-isomers. Resveratrol was purchased from
Changchun Kingherb International Co., Ltd (Changchun, China)
and its purity established as 99% by HPLC analysis. Authentic
resveratrol-3-sulphate was a gift from Dr Tristan Booth (Mount
Royal Pharma, Montreal, Canada), and its identity was corrobo-
rated by mass spectrometry. DMU 212 (3,4,5,40-tetramethoxystil-
bene) was synthesised by Wittig olefination involving the reaction
of 4-methoxybenzyl-tri-phosphonium chloride with 3,4,5-tri-
methoxybenzaldehyde (Potter et al, 1999). This reaction yielded
the -cis and -trans geometric isomers, which were separated by
preparative column chromatography. The -trans isomer was
purified by recrystallisation from ethanol. The DMU 212 analogues
to be used for metabolite identification of 4,40-dihydroxy-3,5-
dimethoxystilbene (4,40-di-desmethyl-DMU 212, DMU 295), 40-
hydroxy-3,4,5-trimethoxystilbene (40-desmethyl-DMU 212, DMU
281), 4-hydroxy-3,5,40-trimethoxystilbene (4-desmethyl-DMU 212,
DMU 291) and 3-hydroxy-4,5,40-trimethoxystilbene (3-desmethyl-
DMU 212, DMU 807) (for structures, see Figure 2) were
synthesised in a similar fashion using the tert-butylmethylsilyl-
protected Wittig precursors, and final deprotection with tetra-
butylammonium fluoride (Potter et al, 1999). 30-Hydroxy-3,4,5,40-
tetramethoxystilbene (30-hydroxy-DMU 212, DMU 214, trans
isomer of combretastatin A4) was synthesised according to the
method of Pettit et al (1995). The identity of newly synthesised
compounds was confirmed by mass spectrometry, nuclear
magnetic resonance spectrometry and infrared and ultraviolet
spectroscopy. Purity was established as at least 99% by HPLC
analysis. The stability of resveratrol in solution is affected by light.
Therefore, care was taken to protect the solutions of compounds
from light. Laboratory chemicals were purchased from Sigma
Chem. Comp. (Poole, UK). Male C57BL/6J mice were obtained
from Charles River Laboratories (Margate, UK). Mice were chosen
for this study, as they frequently are the experimental model of
carcinogenesis used in preclinical chemoprevention studies. Hu-
man-derived malignant colorectal carcinoma cell lines HT-29 and
HCA-7 were obtained from Prof C Paraskeva (Bristol University,
Bristol, UK) and Dr S Kirkland (Hammersmith Hospital, Imperial
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Figure 1 Chemical structures of (A) resveratrol and (B) DMU 212.
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sCollege, London, UK), respectively. Cells used in the experiments
had been subcultured 20–30 times.
Treatments
Animal experiments were conducted as stipulated by Project
Licence 40/2496 granted by the UK Home Office. Experiments were
vetted and approved by the Leicester University Animal Welfare
Committee and complied with the UKCCCR guidelines for the
welfare of animals in experimental neoplasia. Mice aged 8 weeks
(20–22g) received resveratrol or DMU 212 (240mgkg
 1 body
weight, equivalent to 1mmolkg
 1 resveratrol or 0.8mmolkg
 1
DMU 212) via the intragastric route (three animals per time point).
The vehicle was glycerol formal, and the dose volume approxi-
mately 10mlkg
 1. In the case of DMU 212, the vehicle also
contained 10% DMSO. Mice were killed by terminal gaseous
anaesthesia at 10, 30, 60 or 120min postdosing. Blood was collected
by cardiac puncture, and plasma was obtained by centrifugation.
The liver, kidney, lung, heart, brain and gut were excised, and
scrapings were obtained from small intestine and colon. Tissues
were snap-frozen (liquid nitrogen) and stored at  801C until
analysis.
Incubation with liver microsomes
Microsomes were prepared by differential centrifugation of mouse
liver homogenate first at 9 10
3g (20min, 41C), then at 10
5g (1h)
in a Beckman L-8-60 ultracentrifuge (Beckman Coulter UK Ltd,
High Wycombe, Buckinghamshire, UK). The microsomal pellet
was suspended in Tris buffer (50mM, pH 7.4), recentrifuged at
10
5g (1h) and resuspended in Tris buffer. Liver microsomes from
two to four mice were pooled. Microsomes (0.5mg proteinml
 1)
were incubated at 371C with NADPH (1mM), MgCl2 (1mM) and
resveratrol or DMU 212 (1mM) for 20min (final volume: 0.2ml).
The addition of one volume of ice-cold methanol terminated the
reaction. The mixture was vortexed (30s), centrifuged (3min,
13400g) and the supernatant was collected and analysed by HPLC.
For the biosynthesis of resveratrol glucuronide for use as a
reference compound, microsomes were incubated with resveratrol
(1mM) as described above, except that NADPH was replaced by
uridine-diphosphoglucuronic acid (1mM).
Extraction of agents from plasma and tissues
Tissues were homogenised (1:1 volume to tissue mass ratio) in
50mM Hepes buffer (Sigma, Poole, UK) using a hand-held glass
homogeniser. An aliquot (250ml) of homogenate, to which an
internal standard had been added was vortexed, followed by the
addition of acetonitrile (1ml). After vigorous shaking, mixtures
were kept on ice (5–10min) and centrifuged (2800g, 10min, 41C).
The supernatants were dried under a stream of nitrogen and
reconstituted in mobile phase (100ml).
HPLC analysis
HPLC analysis was performed using a Varian Prostar HPLC system
(Varian, UK) with a Pro-Star 230 solvent delivery system, a Pro-
Star 310 UV–Vis detector, a Pro-Star 363 Fluorescence detector, a
410 Varian autosampler and an Ultracarb C18 column
(4.6mm 250mm, 5mm, Phenomenex, UK). The mobile phase
consisted of the three components: aqueous ammonium acetate
(pH 6.5, 50mM), propan-2-ol and acetonitrile. The gradient system
that determined the composition of the eluent concerning these
three components was as follows: for resveratrol 80:10:10 at the
start, 75:10:15 at 10min, 70:10:20 at 15min, 60:10:30 at 17min,
50:10:40 at 20min and 20:10:70 at 25min; for DMU 212
45:10:45 at the start for up to 10min, 20:10:70 at 15min and
10:10:80 at 20min. The flow rate for both methods was
1mlmin
 1.
Internal standards were carbamazepine and 40-methoxy-4-
methyl-trans-stilbene for resveratrol and DMU 212, respectively.
Resveratrol and its metabolites was analysed using UV detection
(325nm), and DMU 212 and its metabolites were determined with
fluorescence detection (335nm excitation, 395nm emission). The
injection volume of samples reconstituted in the mobile phase was
50ml. The preliminary characterisation of metabolites was
achieved by cochromatography using either synthetic standards
or biosynthetically generated resveratrol glucuronide.
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Figure 2 Structures of five putative metabolites of DMU 212.
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sQuantification of resveratrol and DMU 212 was performed using
standard curves constructed with relevant drug concentrations.
The curves were characterised by regression coefficients of
R
2¼0.99 or above. The extraction efficiencies (in percent) for
resveratrol and DMU 212 were as follows: from plasma 102717
and 6772, respectively, from tissues 8677 and 78715, respec-
tively (mean7s.d., n¼5–7). The recovery of the resveratrol
conjugates was approximately 50% that of the DMU 212
metabolites 60%. Therefore, metabolites were not quantitated.
The area under the plasma or tissue concentration vs time curve
(AUC) values were calculated using the trapezoidal rule (Win-
Nonlin v.1.1, Scientific Consultants, USA).
Mass spectrometry
Mass spectrometry was performed using a Quattro Bio-Q tandem
quadrupole mass spectrometer upgraded to Quattro MK II
specifications (Micromass, Manchester, UK) with a pneumatically
assisted electrospray interface. Samples were analysed in positive
ion mode. The temperature was maintained at 1201C, and the
operating voltage of the electrospray capillary was 3.88kV and the
cone voltage was 32V. HPLC conditions used for the on-line
HPLC-mass spectrometric analyses were as described for DMU 212
above.
Effect of agents on growth of HT-29 and HCA-7 cells
Cells were seeded (10
4 per well) in 24-well plates and cultured in
DMEM containing Glutamax I (Life Technologies, Paisley, UK) and
glucose (4.5gl
 1) and 10% foetal calf serum (Gibco, Paisley, UK).
Resveratrol or DMU 212 (1–100mM) dissolved in DMSO was added
to cellular incubates 24h postplating. Cells were counted 72, 96,
120, 144 and 168h postaddition of agents using a Z2 Coulter
Particle Count and Size Analyzer (Beckman Coulter, High
Wycombe, UK). Control cultures contained the vehicle only. The
amount of DMSO added to the incubate did not exceed 0.1%,
which on its own failed to affect the cell growth. The IC50 values
inserted in Figure 5 were calculated from the linear portion of the
cell number-vs agent concentration curves at the 168h time point.
RESULTS
Plasma and tissue levels of resveratrol and DMU 212
Mice received intragastric resveratrol or DMU 212 (1 or
0.8mmolkg
 1), and drug levels were measured in the plasma
and liver, kidney, lung, brain, small intestinal mucosa and colonic
mucosa. These are all tissues in which resveratrol might prevent
malignancy, or delay its onset. For comparison, levels in the heart
were also studied. The results are shown in Figure 3. The plasma
and tissue level data were used to calculate the respective mean
AUC0–120min values (Table 1). Both agents were rapidly cleared
from blood and tissues within an hour of administration (Figure 3).
Concentrations of resveratrol were consistently higher than those
of DMU 212 in the plasma, liver and heart. Levels were similar in
the kidney and lung, while resveratrol concentrations were much
below those of DMU 212 in the brain, small intestinal and colonic
mucosae. The most dramatic discrepancy in levels occurred in the
liver, in which the AUC for resveratrol was five times higher than
that for DMU 212, and in the small intestinal and colonic mucosae,
in which the AUCs for DMU 212 exceeded those for resveratrol by
factors of 10 and 7, respectively (Table 1). Resveratrol levels
peaked after 10min, the first of the time points chosen, and peak
concentrations were 32mM in plasma and 51, 16, 50, 1.2, 75, 960
and 30nmolsg
 1 tissue in the liver, kidney, lung, brain, heart,
small intestinal and colonic mucosae, respectively. DMU 212 levels
reached a peak after 10min, except in the case of the colon, in
which the peak occurred after 30min. The peak levels for DMU 212
were 5mM in the plasma and 8, 11, 11, 5, 10, 7600 and 330nmolsg
 1
tissue in the liver, kidney, lung, brain, heart, small intestinal and
colonic mucosae, respectively. We performed a preliminary
experiment in order to explore whether the difference in
gastrointestinal levels would also be observed when the agents
are administered with the diet, the route often used in preclinical
cancer chemoprevention studies. Agents were admixed with the
diet at 0.2% and fed for 2 weeks. Colonic levels of DMU 212 after
DMU 212 administration exceeded those of resveratrol after
resveratrol administration by two-fold (result not shown).
Table 1 Area under the plasma or tissue concentration time curve
(AUC) for resveratrol and DMU 212 in mice that received these agents
(240mg/kg) i.g
AUC (nmolesml
 1 or g
 1min)
Tissue Resveratrol DMU 212 AUCres/AUCDMU
Plasma 863 246 3.5
Liver 2150 432 5
Kidney 785 566 1.5
Lung 1123 778 1.5
Heart 2072 750 3
Brain 103 193 0.5
Intestinal mucosa 36690 369315 0.1
Colonic mucosa 2869 19256 0.15
AUC values were calculated from the curves shown in Figure 2 using the mean
plasma or tissue concentration values between 0 and 120min postadministration.
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Figure 3 Concentrations of resveratrol (squares, dotted line) and DMU
212 (rhombi, solid line) in the plasma and tissues of mice that received a
single dose of drug (240mgkg
 1) i.g. Values are the mean7s.d. (n¼3).
Star indicates that the values differ significantly (Po0.05, one-way
ANOVA). For details of dosing, extraction and HPLC analyses, see
Materials and Methods.
Pharmacokinetics of resveratrol
S Sale et al
739
British Journal of Cancer (2004) 90(3), 736–744 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sMetabolism of resveratrol and DMU 212
Plasma and tissues of mice, which had received resveratrol or
DMU 212, were investigated using HPLC cochromatography and
mass spectrometry in order to detect and characterise metabolites.
HPLC analysis of liver samples from animals on resveratrol
displayed two peaks (Figure 4A) in addition to the parent
compound. These two species were also observed in the liver,
lung and kidney, but not in the plasma (result not shown). Solvent
eluting from the column with the two peaks was collected, and
peak constituents were isolated and subjected to mass spectro-
metric analysis. Mass spectrometric analysis of peak 1 afforded the
molecular ion m/z¼403, consistent with a resveratrol glucuronide.
Biosynthesis of resveratrol glucuronide using UDP glucuronyl
transferase and liver microsomes generated material, which on
cochromatography eluted with peak 1 (Figure 4A). Mass spectral
analysis did not allow unequivocal confirmation of its structural
assignment as either the 3 or 40 glucuronide. Peak 2 eluted with the
same retention time as authentic resveratrol-3-sulphate and
yielded m/z¼307, consistent with resveratrol sulphate.
Extracts of plasma and liver samples from animals that had
received DMU 212 exhibited several peaks in addition to that of the
parent drug (Figure 4B). Extracts were subjected to cochromato-
graphy with several authentic putative metabolic products of
mono-hydroxylation or O-demethylation of DMU 212. The results
suggest that five of the peaks were 4,40-dihydroxy-3,5-dimethox-
ystilbene (DMU 295, 4,40-di-desmethyl-DMU 212, for structures
see Figure 2), 40-hydroxy-3,4,5-trimethoxystilbene (DMU 281, 40-
desmethyl-DMU 212), 30-hydroxy-3,4,5,40-tetramethoxystilbene
(DMU 214, 30-hydroxy-DMU 212), 4-hydroxy-3,5,40-trimethoxys-
tilbene (DMU 291, 4-desmethyl-DMU 212), and 3-hydroxy-4,5,40-
trimethoxystilbene (DMU 807, 3-desmethyl-DMU 212). Collection
of solvent eluting individual peaks and subsequent tandem mass
spectrometric analysis of solvent extracts confirmed the putative
structural assignment for the four metabolites 4,40-di-desmethyl-
DMU 212 (m/z¼273, Table 2), 40-desmethyl-DMU 212 (m/
z¼287), 30-hydroxy-DMU 212 (m/z¼317) and 3-desmethyl-
DMU 212 (m/z¼287). In extracts of lung and kidney tissues,
these metabolites were also detected, albeit at lower concentrations
(result not shown).
For confirmatory purposes, the metabolism of resveratrol and
DMU 212 was also studied in vitro in suspensions of liver
microsomes fortified with cofactors of cytochrome P450 enzymes.
While HPLC analysis of extracts of the incubation mixture with
resveratrol did not yield any peak in addition to that of the parent
substrate, analysis of incubates with DMU 212 afforded peaks in
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Figure 4 (A) HPLC analysis of liver extracts of mice that received
resveratrol (240mgkg
 1) p.o. (i) and of a mixture (ii) of (i) and
biosynthesised resveratrol glucuronide. Liver tissue was obtained 60min
postadministration. Peak allocation is (1) resveratrol glucuronide, (2)
resveratrol sulphate and (3) resveratrol. The chromatogram is representa-
tive of three. For details of dosing, extraction and HPLC analyses, see
Materials and Methods. (B) HPLC analysis of liver extracts of mice that
received DMU 212 (240mgkg
 1) p.o. (i) a mixture (ii) of (i) with authentic
standards DMU 212, 4,40-di-desmethyl-DMU 212 (DMU 295), 40-
desmethyl-DMU 212 (DMU 281), 30-hydroxy-DMU 212 (DMU 214), 4-
desmethyl-DMU 212 (DMU 291) and 3-desmethyl-DMU 212 (DMU 807).
Liver tissue was obtained 60min postadministration. Peak allocation is (4)
4,40-di -desmethyl-DMU 212 (DMU 295) (5) 40-desmethyl-DMU 212
(DMU 281), (6) 30-hydroxy-DMU 212 (DMU 214), (7) 4-desmethyl-DMU
212 (DMU 291), (8) 3-desmethyl-DMU 212 (DMU 807) (9) DMU 212
and (10) internal standard. The chromatogram is representative of three.
For details of dosing, extraction and HPLC analyses, see Materials and
Methods. (C) HPLC analysis of extracts of an incubate of mouse liver
microsomes with DMU 212 (1mM) (i) and of a mixture (ii) of (i) with
authentic DMU 212, 4,40-di-desmethyl-DMU 212 (DMU 295), 40-
desmethyl-DMU 212 (DMU 281), 30-hydroxy-DMU 212 (DMU 214), 4-
desmethyl-DMU 212 (DMU 291) and 3-desmethyl-DMU 212 (DMU 807).
Incubations were terminated after 20min. Peak allocation is (4) 4,40-di-
desmethyl-DMU 212 (DMU 295) (5) 40-desmethyl-DMU 212 (DMU 281),
(6) 30-hydroxy-DMU 212 (DMU 214), (7) 4-desmethyl-DMU 212 (DMU
291), (8) 3-desmethyl-DMU 212 (DMU 807) (9) DMU 212. The
chromatogram is representative of three. For details of incubation,
extraction and HPLC analysis, see Materials and Methods.
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saddition to that of parent DMU 212 (Figure 4C). In analogy to the
analysis of liver tissue from mice that had received DMU 212,
the incubation mixture was extracted and the extract was subjected
to cochromatographic analysis. The results (Figure 4C) suggest
that 4,40-di-desmethyl-DMU 212, 40-desmethyl-DMU 212, 30-
hydroxy-DMU 212, 4-desmethyl-DMU 212 and 3-desmethyl-
DMU 212 were products of the microsomal biotransformation of
DMU 212.
Effect of resveratrol and DMU 212 on the growth of colon
cancer cells
The growth-modulating ability of resveratrol and DMU 212
were investigated in a preliminary manner in HT-29 and HCA-7
colon cancer cells in vitro. The IC50 values computed form the
growth curves (Figure 5) range from 6 to 26mM, and DMU 212
appears to be a slightly more potent growth inhibitor than
resveratrol.
DISCUSSION
The results presented above suggest that the introduction of four
methoxy groups into the stilbene framework, three of which
replaced the hydroxy moieties in resveratrol, fails to increase the
systemic availability of the molecule in comparison to resveratrol.
This conclusion is borne out by the comparison between
resveratrol and DMU 212 in terms of the concentrations of these
agents in the plasma, liver and heart after oral administration, in
which the availability of DMU 212 was inferior to that of
resveratrol. In contrast, in comparison to resveratrol, DMU 212
was found to be more available in intestinal and colonic mucosae
and in the brain. A priori, it is difficult to predict on theoretical
grounds in what manner such a structural modification might alter
the pharmacokinetic profile of the stilbene molecule. One of the
physicochemical corollaries of this alteration, which undoubtedly
impacts on the pharmacokinetics of the molecule, is the increase in
Table 2 Features of daughter ion spectra obtained by tandem mass
spectrometry of molecular ions (M+H)
+ of DMU 212 and four metabolites
isolated from peaks in high-performance liquid chromatograms of extracts
of livers of micethat had received DMU 212 (240mgkg
 1) and of peaks of
authentic reference compounds
Authentic standard m/z Liver extract m/z
DMU 212 301 (M+H)
+ (55) 301 (M+H)
+ (80)
270 (100) 270 (100)
286 (35) 286 (50)
4,40-Di-desmethyl-DMU 212 273 (M+H)
+ (23) 273 (M+H)
+ (25)
198 (100) 198 (50)
181 (62) 181 (81)
3-Desmethyl-DMU 212 287 (M+H)
+ (10) 287 (M+H)
+ (75)
227 (72) 227 (20)
195 (70) 195 (18)
40-Desmethyl-DMU 212 287 (M+H)
+ (10) 287 (M+H)
+ (60)
256 (100) 256 (100)
272 (80) 272 (47)
30-Hydroxy-DMU 212 317 (M+H)
+ (31) 317 (M+H)
+ (21)
225 (55) 225 (100)
286 (22) 286 (10)
Only three prominent product ions are shown. Relative abundance in percentage is
shown in parentheses.
0
25 000
50 000
75 000
0
25 000
50 000
75 000
0 50 100 150 200
0
500 000
1 000 000
0 50 100 150 200
0
1 000 000
0 50 100 150 200
0 50 100 150 200
IC50 = 19.9±0.3 M IC50 = 11.3±1.1 M
IC50 = 6.0±0.2 M
Cell number
500 000
Incubation time (h)
A B
C D
Figure 5 Effect of resveratrol (A, C) and DMU 212 (B, D) on the growth of HT-29 (A, B) and HCA-7 colon cancer cells (C, D). Symbols indicate the
following agent concentrations: closed squares control cells, open rhombi 1mM, crosses 5mM, closed rhombi 10mM, closed triangles 25mM, open circles
50mM and open squares 100mM.I C 50 values computed for the 168h time point are inserted. Values are the mean7s.d. of four independent experiments.
Pharmacokinetics of resveratrol
S Sale et al
741
British Journal of Cancer (2004) 90(3), 736–744 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
slipophilicity conferred on the stilbene species in DMU 212 by four
methoxy functionalities vis-a ´-vis resveratrol, which has three
hydroxy groups instead. The difference in lipophilicity between
DMU 212 and resveratrol is reflected by the fact that reversed
phase HPLC analysis of a mixture of both agents using the gradient
system described under Materials and Methods for DMU 212
afforded a retention time of 17min for DMU 212, while resveratrol
eluted with the solvent front.
Another factor, which undoubtedly determines the differential
pharmacokinetic properties of resveratrol and DMU 212, is the
divergence in their metabolic profile. Resveratrol is known to
undergo metabolic phase II reactions involving conjugation with
sulphate and glucuronic acid (Yu et al, 2002). Consistent with this
report, we found a resveratrol sulphate and a resveratrol
glucuronide in the liver and other tissues of mice that had
received resveratrol. In contrast to resveratrol, DMU 212 was
subjected to hepatic metabolic oxidation, especially single or
double O-demethylation reactions in the 3, 4 or 40 positions of the
molecule. In addition, we could identify a hydroxylated metabolic
species (30-hydroxy-DMU 212, DMU 214). The spectrum of O-
demethylated and hydroxylated metabolites found in vivo was
accurately reflected by the metabolic profile obtained on incuba-
tion of DMU 212 with NADPH-fortified liver microsomes. These
findings are consistent with the results of recent in vitro
experiments using cytochrome P450 isoenzyme preparations, in
which DMU 212 was found to undergo both aromatic hydroxyla-
tion and O-demethylation reactions primarily catalysed by
isoenzymes of the CYP1 family (Wilsher et al, unpublished). In
analogy, resveratrol was recently found to undergo metabolic
oxidation in vitro to piceatannol (3,5,20,40-tetra-hydroxystilbene),
when incubated with a source of CYP1B1 (Potter et al, 2002b). In
the study described here, piceatannol was not identified as a
metabolite of resveratrol in mice in vivo or in mouse liver
microsomes in vitro. It is conceivable that piceatannol was present
at very low levels, which might have confounded detection by the
procedures used here. The ability to convert resveratrol
to piceatannol has been surmised to be a relatively specific
property of CYP1B1 (Potter et al, 2002b). The lack of the presence
of piceatannol at detectable concentrations in our study in the
mouse is consistent with the notion that CYP1B1 is not expressed
at appreciable levels in mouse liver (Shimada et al, 2003). Overall,
the result described here suggests that hydroxylation to piceatan-
nol is probably not a major metabolic route for resveratrol in the
mouse.
It is conceivable that 4,40-di-desmethyl-DMU 212, 40-desmethyl-
DMU 212, 30-hydroxy-DMU 212 and 3-desmethyl-DMU 212, the
DMU 212 metabolites identified here, undergo phase II metabo-
lism to yield sulphate and/or glucuronide metabolites. However,
conjugates of metabolic species derived from DMU 212 were not
found in the mouse. We cannot exclude that such conjugates were
formed in vivo but not detected. Nevertheless, there were no peaks
indicative of such conjugates, characterised by short retention
times, which could have been subjected to mass spectral
investigation. It has to be stressed that the metabolism studies
described here did not allow quantification of the metabolic
species identified, so that it is not possible to adjudge the
difference between resveratrol and DMU 212 in terms of the
contribution of hepatic metabolism to the overall systemic
clearance of the molecules.
The pharmacokinetic properties of DMU 212 have thus far been
unknown. In contrast, resveratrol has been the subject of several
pharmacokinetic studies, including those in the rat (Soleas et al,
2001) and the mouse (Vitrac et al, 2003), in which resveratrol has
been administered via the oral route. In terms of peak levels and
systemic disappearance, the results outlined above in mice are
consistent with the published studies. The increased drug levels in
the liver, kidney, lung and heart obtained after ingestion of
resveratrol in comparison to those after DMU 212 reflect the
difference in availability observed in the plasma. In contrast, the
levels of DMU 212 in the brain, small intestinal and colonic
mucosae after DMU 212 administration exceeded levels of
resveratrol measured after resveratrol intake. The higher avail-
ability of DMU 212 in the brain suggests that it is capable of
crossing the blood–brain barrier more easily than resveratrol,
which is probably a consequence of the higher lipophilicity of
DMU 212. The discrepancy between resveratrol and DMU 212 in
concentration achieved in the small intestine and colon may be a
corollary of their differential metabolic susceptibilities. The lower
availability of resveratrol compared to DMU 212 may be the
consequence of the high propensity of resveratrol to undergo
conjugation reactions catalysed by enzymes (De Santi et al, 2000;
Kuhnle et al, 2000; Marier et al, 2002), which are abundantly
present in the gut (Eisenhofer et al, 1999). In contrast, on the basis
of the fact that activities of oxidising enzymes in the gut are much
lower than in the liver (Doherty and Charman, 2002), the ability of
the gut mucosa to O-demethylate or hydroxylate DMU 212 is
arguably much lower than its ability to biotransform resveratrol by
conjugation. On the speculative assumption that DMU 212 and
resveratrol share biochemical mechanisms germane to cancer
chemoprevention and that DMU 212 is not inferior to resveratrol
in intrinsic potency, this observation hints at a potential advantage
of DMU 212 over resveratrol when applied as an experimental
colorectal cancer chemopreventive agent. The superior growth-
inhibitory and apoptotic potency of DMU 212 in comparison to
resveratrol in transformed human lung-derived cells (Lu et al,
2001) is consistent with this hypothesis. Peak levels of DMU 212
that were achieved in the colonic and small intestinal mucosae in
mice exceeded those required to cause significant arrest of
transformed lung cell growth in vitro (10mM) by factors of 32
and 760, respectively. Furthermore, the results of our preliminary
assessment of the colon cancer cell growth-inhibitory properties of
resveratrol and DMU 212 suggest that the concentrations of either
agent required to inhibit growth, with IC50 values between 6 and
26mM, are comfortably within the range achieved in the colorectal
tract of mice that received these agents at the oral doses used in the
study described here, 240mgkg
 1.
In the light of the suggestion that resveratrol at 0.01% in the
drinking water (constituting a dose of B15mgkg
 1 per day)
decreased adenoma multiplicity in the Apc
Min/þ mouse model
(Schneider et al, 2001), the results described here render a
comparison of resveratrol and DMU 212 in this model appropriate,
and such experiments are currently planned in this laboratory.
However, it is important to add a note of caution, because the
chemopreventive efficacy of resveratrol in this model is highly
contentious, as borne out by two contradictory abstracts published
subsequent to the paper by Schneider et al (2001). These abstracts
suggest that in the same murine model, dietary doses comparable
to, or much higher than, those used by Schneider et al were
completely ineffective (Ziegler et al, 2001) or, in the case of a
dietary daily dose of 500mgkg
 1 for 14 days, reduced adenoma
load, but did so only in female mice and not at all in male mice
(Gignac and Bourquin, 2001).
In conclusion, the work described here provides an initial
pharmacokinetic groundwork, which can contribute to rational
decision making as to the choice of resveratrol analogues that
should be selected for comparative testing for cancer chemopre-
ventive potency in preclinical models. DMU 212 showed more
favourable pharmacokinetic properties than resveratrol, in that it
yielded higher levels of drug in the small intestinal, colonic
mucosae and brain. Buttressed by our recent finding that DMU 212
is devoid of any toxicity in rats when administered at single doses
of up to 40mgkg
 1 via the i.v. route or up to 400mgkg
 1 when
administered p.o. (Verschoyle et al, unpublished), the results
presented here render the exploration of DMU 212 side by side
with resveratrol for chemopreventive efficacy in rodent models of
colorectal carcinogenesis propitious.
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